Neurocrine Biosciences holds the cleaner structural position, with growth as the main driver and valuation adding further support. BioMarin Pharmaceutical does not offset that deficit through any equally strong structural edge elsewhere. The market setup is mixed, without a decisive signal in either direction. The market is not adding a decisive signal either way — the structural read carries the weight.
The comparison is based on similar long-term financial trajectories, not sector labels. Both peer scores are relative to the Russell 1000 universe, making them directly comparable.
Growth still does most of the heavy lifting in this comparison. The overall score gap is 26 points in favour of Neurocrine Biosciences, Inc..
This comparison is anchored in long-term financial trajectory similarity within the selected peer universe.
This level of similarity points to a meaningful structural match, though not a tight one.
The strongest overlap appears in revenue stability and investment intensity.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
The largest gaps do not all point in the same direction.
Left means cheaper relative valuation. Higher means stronger structure.
Neurocrine Biosciences, Inc. looks stronger on relative valuation, while the broader price setup remains mixed.
Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.
Where BMRN and NBIX each sit in their own 5-year price and valuation history.
Describes historical entry positioning only. Descriptive — not investment advice.
Growth adds another layer to the lead, with a very wide gap in revenue growth between the two companies.
BioMarin Pharmaceutical Inc. still carries lower volatility exposure — that difference is real enough to prevent the comparison from becoming one-sided.
Growth is the clearest driver, and valuation also supports Neurocrine Biosciences, Inc.'s broader structural position.
Break down the BMRN vs NBIX comparison across all dimensions with the full interactive tool.
Explore how BMRN and NBIX each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.